



ROFIN-SINAR TECHNOLOGIES

## **- PRESS RELEASE -**

Contact: Thorsten Frauenpreiss  
Günther Braun  
ROFIN-SINAR  
734-455-5400  
- or -  
011-49-40-733-63-256

### **ROFIN-SINAR SELLS MEDICAL LASER BUSINESS TO WAVELIGHT**

**Plymouth, MI / Hamburg, Germany, July 17, 2001** – ROFIN-SINAR Technologies, Inc. (NASDAQ: RSTI), one of the world's leading developers and manufacturers of high performance laser beam sources and laser-based solutions, announced today that it intends to sell the medical laser business of Carl Baasel Lasertechnik GmbH, Starnberg, a majority-owned subsidiary of Rofin-Sinar Laser GmbH, to WaveLight Laser Technologie AG, Germany.

Under the terms of this agreement WaveLight Laser Technologie AG will acquire Carl Baasel Lasertechnik's medical laser business, which deals with the development, manufacturing and distribution of laser systems for aesthetic surgical applications. The integration of the medical laser business into WaveLight's corporate structure is expected to be fully accomplished by the end of this year at the latest.

Since last year's acquisition of the Baasel Lasertech Group, Rofin has streamlined its business areas and focuses now on three core business units: Macro, Micro and Marking. As there is little overlap between the core business areas and aesthetic surgical applications and the markets for laser medicine, the Company decided to sell this business segment.

"Rofin and WaveLight took a strategically important step together", commented Carl F. Baasel, founder and managing director of Carl Baasel Lasertechnik GmbH. "Due to the excellent possibilities of integration into WaveLight's business activities, the medical laser business will experience faster growth, and our company will be able to concentrate more on its core business areas: laser micro and marking products and system solutions for industrial applications."

Max Reindl, founder and CEO of WaveLight Laser Technologie AG explains the reasons for this purchase: "We are pleased to have the opportunity to complete our product portfolio with such innovative laser products. We expect valuable synergistic effects in the marketing, distribution and manufacturing of products for aesthetic surgical applications. The medical laser business activities of Rofin match absolutely with our growth strategy in the aesthetics business area."

With operational headquarters in Plymouth, Michigan and Hamburg, Germany, Rofin-Sinar Technologies, Inc. designs, develops, engineers and manufactures laser sources and laser-based system solutions for a wide range of applications. With production facilities in the US, Germany, UK, Singapore and Japan, Rofin-Sinar is one of the world's leading developers and manufacturers of industrial lasers and currently has more than 14,000 laser units installed

worldwide and serves more than 2,500 customers. Rofin-Sinar's shares trade on the NASDAQ National Market System under the symbol RSTI. Since July 2, 2001, Rofin-Sinar's common stock is also traded under the German Securities Identification Number 902 757 on the German Neuer Markt at the Frankfurt Stock Exchange. Additional information is available on Rofin-Sinar's home page: <http://www.rofin.com>.

Certain information included in this press release is forward-looking and is subject to important risks and uncertainties that could cause actual results to differ. Actual results could differ materially based on numerous factors, including currency risk, competition, risk relating to sales growth in CO<sub>2</sub>, diode, and Nd:YAG lasers, cyclicalities, conflicting patents and other intellectual property rights of third parties, potential infringement claims and future capital requirements. These forward looking statements represent the Company's best judgment as of the date of this release based in part on preliminary information and certain assumptions which management believes to be reasonable. The Company disclaims any obligation to update these forward-looking statements.

###